Importantly,compound 40 also showed strong therapeutic efficacy incombination with the DFG-out Raf-inhibitor sorafenib in HCC cellsand displayed an increased ability to induce oxidative stress andan ER stress response with concomitant Raf inhibition. The gene discussed is RAF1; the disease is hepatocellular carcinoma.